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Summary Sequential fine-needle aspirates (FNAs) for cytodiagnosis and flow cytometry were taken from 21
patients with primary breast carcinoma at intervals ranging from 1 to 3 months after the commencement of
first-line tamoxifen therapy. Nine patients achieved a sustained complete or near complete response over a 3-9
month period. The tumour cells from seven out of nine of these patients were initially aneuploid, while the
remaining two patients had diploid tumours. An analysis of sequential FNAs showed that, in three out of the
seven aneuploid tumours, only benign epithelial cells could be detected by cytology in the post-tamoxifen
sample. In the remaining six cases, including the two diploid tumours, there was no change in ploidy but a
reduction in S-phase fraction (SPF) to approximately 50% of the pretreatment level. In all cases, these changes
in ploidy or SPF were seen with a mean lead time of 4 months before the tumour had reached clinical
complete remission. None of these patients have relapsed after a mean follow-up period of 18 months. The
tumours of 12 patients achieved no more than a temporary partial response to primary tamoxifen therapy. In
seven out ofeight of these cases, which were all initially aneuploid, sequential FNAs during tamoxifen therapy
revealed either an increase or no change in the SPF with the tumour remaining aneuploid. In the remaining
four cases the tumours were all recorded as being diploid in the pretreatment sample. However, although three
of these cases had a temporary partial response to tamoxifen, an aneuploid component was picked up in
repeat sequential FNAs with a mean lead time of 5 months before clinical confirmation of eventual disease
progression. We conclude that changes in ploidy and SPF detected by flow cytometry may predict initial
response and the likelihood of relapse of breast tumours to tamoxifen before clinical changes become evident.
These data justify a larger study.
It is recognised that breast tumours with an oestrogen recep-
tor level > 10 fmol per mg of protein have a greater chance
of responding to endocrine therapy such as tamoxifen
(Allegra et al., 1980; Rubens & Hayward, 1980; Young et al.,
1980; Fisher et al., 1983). Studies have also demonstrated
that the higher the oestrogen receptor level the greater the
chance of response (Hayward et al., 1977; Paridaens et al.,
1980; Campbell et al., 1981; Osborne et al., 1980; Fisher et
al., 1983). The oestrogen receptor level does not, however,
correlate with the duration of response to treatment and
therefore gives no indication of relapse in an individual
tumour (Allegra et al., 1980).
There has been no previously reported biological predictor
of relapse to tamoxifen therapy. Serum tumour markers
(such as CA15-3) have only limited use and, apart from the
observation ofprogressive clinical disease, there is no method
of investigation that can determine whether a primary
tumour is responding to primary medical treatment, includ-
ing tamoxifen. As this is a late event in the natural history of
the disease, it could be of benefit to predict relapse before it
becomes clinically evident. This is ofparticular importance as
the role of primary tamoxifen alone in the treatment of early
breast cancer is now highly controversial. A recent update
from the CRC tamoxifen study for patients >70 years of age
suggested a possible worse survival for patients treated by
tamoxifen alone in comparison with patients treated by
immediate surgery (Bates et al., 1992). It is theoretically
possible that earlier detection of relapse before it became
clinically evident could reduce any survival disadvantage
caused by ineffective primary tamoxifen therapy.
Tamoxifen has been shown to have significant effects on
the proliferation characteristics of breast cancer cell lines
grown in culture (Sutherland et al., 1983; Osborne et al.,
1984; Lykkesfeldt et al., 1986). While some investigations in
vivo have failed to confirm these findings (Baildam et al.,
1987; Brunner et al., 1989), Clarke et al. (1993) have
observed a reduction in expression of the proliferation-
related marker, Ki67, in human breast tumours during treat-
ment with tamoxifen. Although tamoxifen can take many
months to achieve its full clinical effect, none of the
previously reported studies have analysed the long-tern
effects of tamoxifen on S-phase fraction (SPF) or DNA index
(DI) of the tumour.
The aim of this pilot study was first to determine the
reliability and reproducibility of repeat sequential fine-needle
aspirates (FNAs) in determining the DNA content from
breast tumours in vivo and, then, using this technique, to
determine whether flow cytometry of FNAs could be used to
monitor and predict the likely response of these primary
breast tumours to tamoxifen.
We report the results on 21 patients undergoing treatment
with primary tamoxifen. The data suggest that changes in the
DI and SPF may be useful parameters in the management of
these patients.
Materials and methods
Patients
From January 1991 to June 1992, 27 patients with primary
breast tumours were treated with tamoxifen alone either as
part of the CRC trial ofprimary tamoxifen versus immediate
surgery in patients over 70 years (Bates et al., 1992) or in
patients considered unfit for surgery with or without meta-
static disease but suitable for primary endocrine therapy.
Any patient who had been previously treated with any other
form of systemic therapy (endocrine or chemotherapy) was
excluded from the study. Twenty-one of these patients were
included in this study, six being excluded because samples
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inadequate for flow cytometry were obtained (criteria for
exclusion of samples are given below).
The staging of these tumours was based on the TNM
classification. Sixteen out of 21 (76%) cases were T2
tumours; three patients had metastatic disease at the time of
presentation (Table I).
FNAs were taken from patients on tamoxifen therapy at
intervals ranging from between 1 and 3 months. At the same
time the tumour response to therapy was also recorded using
standard UICC criteria. No further repeat samples were
taken on any patient once they had achieved a complete or
near complete response, nor were they taken once disease
progression had been observed clinically and the patient
taken off tamoxifen.
In a control group of 17 patients, repeat cytological
samples were taken from the same tumour with a 1 week
interval without intervening treatment.
Preparation ofcytological aspirates
A cell suspension was prepared for each FNA using 2 ml of
minimum essential medium (MEM) containing 25 mM
HEPES buffer and phenol red. A 1.2 ml volume of this cell
suspension was then cytocentrifuged at 500 r.p.m. onto 12
slides, suitable for long-term storage at -80°C. The residual
0.8 ml of suspension fluid was snap frozen in liquid nitrogen
and stored at
- 800C until required for flow cytometric
analysis (see below).
One of the slides was stained with May-Grunwald-Giemsa
for cytodiagnosis and scorded for the presence of malignant
cells and graded (CO = blood only; Cl = benign epithelial
cells and blood; C2 = predominantly benign epithelial cells;
C3 = malignant cells, <50 cells/slide; C4 = predominantly
malignant, 50-400 cells per slide; C5 = cellular, >400 malig-
nant cells per slide). Any sample found to be diploid on flow
cytometry was only considered to be malignant if the
cytological aspirate was cellular and shown to contain
predominantly malignant cells (that is C4 or C5). It would
otherwise be impossible to tell whether the results obtained
were from benign duct epithelial cells rather than car-
cinoma.
Flow cytometric analysis
All the reagents were bought from Sigma (Poole, Dorset,
UK).
The suspension fluid remaining (0.8 ml) was thawed at
370C, centrifuged at 1,000 r.p.m. for 10 min and the pellets
resuspended in 200 tLI of a stain-detergent solution consist-
ing of 1 g of trisodium citrate, 564 mg of sodium chloride,
300 tl of Nonidet P-40, 10 mg of propidium iodide in 11 of
distilled water. To this suspension of nuclei, 20 gsl of a
1 mg ml-' solution of RNAse was added and the suspension
kept on ice for 30min before analysis.
The nuclei were analysed on an Ortho Cytofluorograf 50H
equipped with a Spectra Physics argon-ion laser producing
200mW at 488 nm and an Ortho 2150 computer system.
Forward and orthogonal light scatter, the peak and area of
the red fluorescence were recorded. After gating on a cyto-
gram of peak versus area of the red fluorescence to remove
debris and clumped nuclei from the analysis (Ormerod,
1990), a cytogram of orthogonal versus forward light scatter
was displayed on the monitor. By gating on light scatter,
separate DNA histograms of the tumour and normal cells
were produced. The histograms were transferred to an IBM-
compatible PC; further analysis and production of diagrams
was performed using software written by one of the authors
(M.G.O.).
All the samples, contained some normal cells (diploid, low
light scatter). The position of the GI peak from the DNA
histogram of the normal cells was compared with that of the
G1 peak from the tumour and used to compute the DI
(tumour-G1-channel/normal-G,-channel). The sample was
recorded as aneuploid only if a clearly separate peak could
be distinguished. Any sample with a coefficient of variation
(CV) across the G, peak > 10% was excluded from the
analysis. A typical histogram is shown in Figure 1. The
percentage of cells in S-phase was estimated by placing a
region in the centre of the histogram, which contains only
cells in S-phase, and doubling the percentage obtained. This
procedure gives an estimate of S-phase when, as in this case,
the DNA histogram is unperturbed (Ormerod, 1990). It was
not possible to measure SPF in hypodiploid (DI<1.0)
tumours, in tumours with more than one aneuploid popula-
tion and in cases where the diploid cells had a distinct G2
peak which could not be separated from an aneuploid SPF
by gating on light scatter. Nor was it possible to interpret the
histograms when the DNA was badly degraded (that is CV
across GI >10%).
In a separate study of 352 FNAs taken from breast
tumours, we have found that DI could be measured in 78%
and SPF in 60% of the samples.
Tumour response
Tumours were classified into four groups depending on the
response to treatment, based on the UICC classification
Table I Relationship between flow cytometric results and clinical response
Clinical
Patient T stage/M Ploidy/(DI) Ploidyl(DI) S-phase S-phase Change in response (no.) Ti -T4 pre-tamoxifen post-tamoxifen pre-tamoxifen post-tamoxifen SPF (maximum)
DA (1) T2 A (1.2) D (C3) Insufficient Insufficient N/P CR WW (2) T2 A (1.24) D (C2) Insufficient Insufficient N/P CR GM (3) T2 A (1.4) D (C2) 14 Insufficient N/P CR FH (4) T2 A (1.4) A (1.3) 22 8 -14 CR AF (5) Ti A (1.7) A (1.6) 9 5 -4 CR WG (6) T2 A (2.4) A (2.35) 12 2 -8 CR MP (7) T2 A (1.85) A (1.87) 15 4 -11 CR JT (8) T2 D (C5) D (C5) 22 2 -20 CR DP (9) T2 D (C5) D (C5) 5 2 -3 CR RB (11) T4 D (C5) A (2.2) 10 5 N/A PR GD (13) T2 D (C5) A (1.3) 5 25 N/A PR JT/2 (15) T2/M1 A (1.2) A (1.3) 7 9 +2 PR CG (18) T3 A (1.45) A (1.34) 9 14 +5 PR EV (10) T2 A (1.3) D (C5), A (1.44) 21 21 0 PD IE (12) T2 D (C4) A (1.3) 5 26 N/A PD EJ (14) T2/Ml D (C5) A (1.3) 4 5 N/A PD FS (19) T2/M1 A (1.8) A (1.7) 10 9.5 -0.5 PD RB/2 (20) T2 A (1.7) A (1.7) 9 11 +2 PD JM (21) T4 A (1.1) A (1.7) 1 13 +12 PD
CR, complete response; A, aneuploid; C2, benign; PR, partial response; D, diploid; C3, C4, C5, malignant; NC, no change; N/A, not applicable (ploidy change during treatment); N/P, not possible to calculate (insufficient data); PD, progressive disease; M1, metastases.FLOW CYTOMETRY OF FNAS FROM HUMAN BREAST CANCER
(Hayward et al., 1977): those tumours which achieved a
complete or near complete response (residual thickening too
small to measure clinically) (CR), partial response (>50%
reduction in tumour size) (PR), stable disease (<25% in-
crease or <50% decrease in tumour size) (NC) and those
with progressive disease (>25% increase in tumour size)
(PD).
In 14 of the 21 cases of the study arm, patients were seen
initially 1 month after starting tamoxifen. In the remaining
seven cases (patient nos. 1, 9, 12, 14, 17, 18 and 20 in Tables
I and I1), the first visit to the clinic was arranged at 3
months. In all cases any subsequent visits were at 3 monthly
intervals.
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Results
Sequential FNAs with no intervening treatment
In the series of 17 cases, the DI and SPF were measured on
aspirates that were taken 1 week apart from the same tumour
with no intervening therapy (Figures 2 and 3). There was
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Figure 2 Comparisons of DIs on FNAs from breast tumours
taken at 1 week intervals with no intervening therapy. Linear
regression analysis gave: y = 0.93x + 0.85; r = 0.93.
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Figure 1 DNA histogram from an FNA of an aneuploid breast
tumour showing diploid cells in G0 (D, GI) and aneuploid cells in
GI (A, GI), S and G2 phases of the cell cycle. DNA index
(DI) = 1.3; aneuploid fraction = 86%; tumour cell cycle:
GI = 92%, S = 3%, G2= 4%.
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Figure 3 Comparison of SPFs on FNAs from breast tumours
taken at I week intervals with no intervening therapy. Linear
regression analysis gave: y = I.Olx + 1.33; r = 0.95.
Table II Interval between a change in flow cytometric parameters and the final clinical response. This clinical response at the time
a change in DNA was detected is also shown
Months on tamoxifen Lead time (months)
Clinical before change in DNA between DNA change and
Patient response detected (corresponding final clinical response ( ) Follow-up
initials (no.) (maximum) DNA change clinical response duringfollow-up period (months)
D.A. (1) CR A+D 3 (PR) 3 (CR) 24
WW. (2) CR A+D 3 (PR) 3 (CR) 24
G.M. (3) CR A+D I (PR) 3 (CR) 18
F.H. (4) CR SPF down 3 (PR) 4 (CR) 18
A.F. (5) CR SPF down 1 (PR) 3 (CR) 20
W.G. (6) CR SPF down 1 (NC) 6 (CR) 12
M.P. (7) CR SPF down 1 (NC) 9 (CR) 12
J.T. (8) CR SPF down 3 (NC) 3 (CR) 12
D.P. (9) CR SPF down 3 (NC) 3 (CR) 24
E.V. (10) PD A+D-*A 1 (NC) 9 (PD) 10
R.B. (I1) PR D+A 3 (PR) 6 (NC) 12
I.E. (12) PR D->A 9 (PR) 6 (PD) 15
G.D. (13) PR D-A 9 (PR) 6 (NC) 18
E.J. (14) PD D-A 3 (NC) 3 (PD) 6
J.T./2 (15) PD SPF NC I (NC) 6 (PD) 7
G.M. (16) PD SPF NC 1 (NC) 6 (PD) 7
H.S. (17) PR SPF NC 3 (PR) 15 (NC) 18
F.S. (19) PD SPF NC 1 (NC) 6 (PD) 7
R.B./2 (20) PD SPF NC 3 (NC) 6 (PD) 9
J.M. (21) PD SPF UP I (NC) 3 (PD) 4
CR, complete response; PR, partial response; PD, progressive disease; NC, no change; A-1D, aneuploid to diploid; D-*A,
diploid to aneuploid; SPF, S-phase fraction.
1213
G,
S G21214 I.N. FERNANDO et al.
good concordance in the estimate of the DI between the two
aspirates (correlation coefficient = 0.93). In only one case was
a sample found to be diploid in one aspirate and aneuploid
in the other; the difference in DI was small, 1.0 in the first
aspirate and 1.1 in the repeat. In nine cases a value for the
SPF was obtained from both samples. There was a correla-
tion coefficient of 0.95 between the recorded results (Figure
3).
Sequentialfine-needle aspirates after commencing tamoxifen
therapy
The results showing changes in DI and SPF after starting
tamoxifen therapy in relation to the clinical response of the
tumour are presented in Table I. Not all the FNAs from the
patients reported are presented because the table would have
been too large to handle. The table includes the first FNA
from each patient to show any change in the DNA histo-
gram. None of the omitted samples showed any inconsistency
with those given. Table II shows the lag between the time
that a change in the DI was first detected in relation to the
maximum and final recorded response of the tumour during
the follow-up period.
The mean value for change in SPF (Table I) between pre-
and post-tamoxifen FNAs in tumours achieving a complete
response (patients 4-9) was - 10% (s.d. = 5.2%). For non-
responding tumours (patients 15-21) the difference was 2.5%
(s.d. = 4.7%). An analysis of these data using a
Mann-Whitney non-parametric test has shown this difference
to be significant (P<0.01). Only tumours in which the DI
remained unchanged after tamoxifen therapy were included
in the computations to ensure that the same tumour cell
population was being considered between pre- and post-
treatment samples.
Patients achieving complete response (CR) to tamoxifen
Nine patients achieved a complete response, and after a
median follow-up of 18 months none of these patients had
relapsed. Three patients (patients 1-3) had a reduction in
ploidy from aneuploid to diploid, but this was associated
with a disappearance of malignant cells from the post-
tamoxifen FNA (scored as C2 or C3). It is not possible to
differentiate between benign epithelial cells and malignant
diploid cells on the flow cytometer, and the change in ploidy
was probably caused by insufficient malignant cells in the
aspirate.
In the other six cases (patients 4-9) there was a reduction
in SPF alone (with no change in ploidy) of greater than 50%
of the pretreatment level with a >3% difference in the
absolute values (see Figure 4). This degree of difference was
not seen in any cases of repeat sampling with no intervening
therapy and could not simply be explained by intratumoral
heterogeneity alone. The reduction in SPF was seen on
average 4.5 months (Table II, patients 4-9) before clinical
CR was achieved, although the patients had been on tamoxi-
fen on average for only 2 months.
Patientsfailing to show complete response (PR or PD)
In four cases (patients 11-14), in which the tumours were
diploid in the pretreatment sample, a change to aneuploid
(see Figure 4) was detected in a FNA taken on average 6
months after starting tamoxifen treatment. In two cases
(patients 12 and 13), a preceding sample taken while the
patient had been on tamoxifen for at least 3 months had also
been recorded as diploid. In three of these cases (patients
11-13) the tumours achieved a partial response to tamoxifen
and the changes in ploidy were detected even while the
patient was still in partial remission. However, all four
patients subsequently showed clinical signs of tumour pro-
gression which occurred with a mean lead time of 5 months
after detecting the change in ploidy. In two cases (patient 11
and 13) this clinical progression was still <25% and was
therefore scored into a NC category.
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Figure 4 DNA histograms from FNAs taken during tamoxifen
therapy. Top: Patient no. 4 showing a decrease in SPF during
therapy.
Sample GI (%) S (%) G2 (%)
Pretreatment (a) 70 22 8
Post-tamoxifen (b) 80 2 18
Bottom: Patient no. 13 showing a change from diploid to
aneuploid. C, pretreatment; D, post-tamoxifen (9 months).
In six cases (patients 15-20) repeat sequential aspirates
showed no change in ploidy with either no change or a rise in
SPF of >50% with a > 3% difference in the absolute value.
In four of these cases there was no clinical response to
tamoxifen and all showed tumour progression of >25%
with a mean lag time of 7 months between the recorded
post-tamoxifen sample and clinical progression. In two cases
(patients 17 and 18 in Table II) there was a short-lived
partial response with one of them showing tumour progres-
sion which had not quite achieved the UICC definition ofPD
at the time ofcompleting the study (patient 18). The case was
therefore recorded into a NC category. Patient 21 showed a
change in the DI from 1.1 to 1.7 and an increase in SPF;
tamoxifen treatment was ineffective in this patient.
In one case (patient 10) a sample taken 1 month after
commencing tamoxifen showing a reduction in ploidy from
aneuploid to diploid, with the latter sample being cellular
and containing predominantly malignant cells. In this parti-
cular case a repeat FNA taken before therapy had also
shown a diploid peak, but with a CV > 10%, which was
therefore removed from the analysis. This case clearly dem-
onstrates the problem of intratumoral heterogeneity and no
interpretation could be drawn on the changes in DNA con-
tent after tamoxifen therapy in the particular example.
Discussion
Reproducibility ofFNAs
When FNAs were taken at weekly intervals with no interven-
ing therapy, there was good concordance in the DIs and
SPFs measured on the two samples. However, it should be
noted that no data are available on the variation of DI or
SPF over periods longer than 1 week with no intervening
therapy as this was not considered ethical in a clinical study.
These data agree with several other reports (Prey et al., 1985;
Erhardt & Auer, 1986; Remvikos et al., 1991) which have all
shown good correlation between sequential FNAs from the
same tumour. Only one study (Mullen & Miller, 1989) has
commented on significant variation in DNA analysis caused
by intratumoral heterogeneity between two fine-needle
aspirates taken from the same tumour. Even here a com-FLOW CYTOMETRY OF FNAS FROM HUMAN BREAST CANCER 1215
parison of DI between two needle aspirates showed less than
5% variation in 10 out of 11 cases.
Greater variation has been obtained when comparing
FNAs with paraffin section from the same tumour (Green-
baum et al., 1984; Prey et al., 1985; Kalloniemi, 1988). This
may explain why some studies in which both techniques have
been employed have failed to obtain any consistent changes
in DNA content in breast tumours after tamoxifen therapy
(Baildam et al., 1987).
These reported differences may also relate to other factors
such as tumour size. It is more difficult to sample uniformly
across a large tumour which is also more likely to be hetero-
geneous in terms of the proliferation characteristics of its
individual cells. It should therefore be noted that in this
study 18/21 of cases had tumours <5 cm in diameter. Also,
considerable care was taken to sample widely from several
areas within the same tumour. This is not possible when a
paraffin-embedded tissue section is taken from the tumour
after surgery if only one 40-nLm section of tumour is taken for
analysis.
The results of this study have shown that, providing any
sample with a CV > 10% on flow cytometry or diploid with
<100 malignant cells per cytospin slide was removed from
the analysis, significant intratumoral heterogeneity was seen
in only one case (patient 10).
In this pilot study, we were able to monitor changes in
only 21 out of 27 patients. However, this was part of a
multifactorial study. Material for 12 cytospins was taken
from the aspirate before storing the remainder of the sample
for flow cytometry. We would expect a higher success rate
from aspirates taken for one cytospin (conventional cyto-
logical stain) and flow cytometry only. If these measurements
are shown to be of real benefit in patient management,
patient recall to obtain a repeat sample would be
justified.
The use ofan FNA to monitor treatment
Considering the data from the FNAs taken sequentially dur-
ing treatment, the clearest indication of successful therapy
was a failure to observe malignant cells by conventional
cytology in the post-treatment sample. This was also reflected
in the flow cytometry in that only diploid cells were detected
in the post-treatment samples of what had previously been
recorded as aneuploid tumours (patients 1-3). However, in
six patients, a reduction in the SPF was recorded by flow
cytometry before the disappearance of malignant cells from
the aspirate (patients 4-9).
In seven patients, tumours were shown to be aneuploid
and sequential FNAs showed either no change or a rise in
SPF. These cases showed eventual tumour progression with
an increase in tumour size which in only one patient was still
insufficient (<25%) to classify as PD. There was a median
lead time of 7 months between the repeat FNA result and
eventual tumour progression (see Table II, patients
15-21).
The difference in SPF between pre- and post-treatment
samples for tumours achieving a complete response versus
those only reaching a partial response or less was
significantly different (P<O.O1) even with the small numbers
in the study.
In four patients (patients 11-14) a change from diploid to
aneuploid was observed while the tumours were still in par-
tial remission and on average after only 6 months of therapy.
All these cases eventually showed clinical evidence of tumour
progression. However, the change in ploidy was picked up
with a mean lead time of 5 months before progression was
detected clinically. This change was presumably caused by
regression of the main diploid component and subsequent
growth of a small aneuploid component already present
within the tumour or from clonal development of a new cell
population (Nowell, 1976). This is consistent with data (Kute
et al., 1985) showing that diploid tumours are more likely to
be oestrogen receptor positive and hence respond to tamoxi-
fen.
A change from diploid to aneuploid or a rise in SPF may
reveal a failure in therapy even before changes in tumour size
become evident. Conversely, a rapid decrease in the number
ofmalignant cells in an FNA which was initially cellular or a
fall in SPF may indicate a complete response. These data
suggest that monitoring the changes in DI and SPF in
patients on tamoxifen may enable the physician to select
which patients are most likely to obtain a complete response
or not to primary tamoxifen therapy. A larger study to
investigate these changes further is therefore warranted.
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